meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - adjuvant
13
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
ribociclib based treatment
HER inhibitor
HER2 inhibitor
neratinib based treatment
neratinib
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
pembrolizumab based treatment
pembrolizumab alone
mTOR inhibitors
everolimus
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
no study with result for this clinical condition